|
Jun 4
|
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
|
|
Jun 4
|
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
|
|
Jun 4
|
Sanofi announces new data from two clinical studies on Sarclisa
|
|
Jun 3
|
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
|
|
Jun 3
|
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
|
|
Jun 3
|
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
|
|
Jun 2
|
Sector Update: Health Care Stocks Retreat in Afternoon Trading
|
|
Jun 2
|
Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of
|
|
Jun 2
|
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
|
|
Jun 2
|
Top Midday Stories: Steel Stocks Soar After Trump Doubles Steel Tariffs; Bristol Myers Squibb, BioNTech to Collaborate on Tumor Therapy
|
|
Jun 2
|
M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal
|
|
Jun 2
|
Sanofi to acquire Blueprint Medicines, Boeing upgrade
|
|
Jun 2
|
Sanofi to expand immunology offerings with Blueprint Medicines
|
|
Jun 2
|
Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
|
|
Jun 2
|
Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio
|
|
Jun 2
|
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
|
|
Jun 2
|
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
|
|
Jun 2
|
Sanofi to acquire Blueprint for up to $9.5B
|
|
Jun 2
|
5 Things to Know Before the Stock Market Opens
|
|
Jun 2
|
Trending tickers: Tesla, Palantir, Sanofi, Babcock and Indivior
|